Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that has shifted away from its earlier TCR-T cell therapy oncology program and is now focused primarily on an internally developed preclinical small-molecule oral obesity program. The company was originally built around adoptive TCR-T cell therapy for solid tumors, but in 2023 it reprioritized the business and began winding down its Phase 1/2 TCR-T Library trial. Alaunos is also actively evaluating strategic alternatives such as asset sales, partnerships, mergers, reverse mergers, or capital raises to preserve value and extend its runway. It has not generated product revenue and remains dependent on external financing while it advances preclinical work and manages a reduced operating footprint.
−84 360,0 %
−83 520,0 %
−50,0 %
2.45
2.45
| % | |
|---|---|
| Preclinical obesity therapeutics | 0% Internally developed oral small-molecule candidates for obesity and related metabolic disorders. |
| Cell therapy oncology platform | 0% Adoptive TCR-T cell therapy programs and related platform assets developed for solid tumors. |
| Legacy licensing and royalties | 100% Royalty income and potential monetization of previously developed oncology assets and platforms. |
Alaunos does not currently sell commercial products to patients or hospitals, so its direct customer base is limited...
Companies that may license the TCR library, hunTR platform, or obesity program assets to gain access to differentiated science and development optionality.
Public and private investors that provide the cash needed to fund preclinical work, wind-down costs, and corporate restructuring.
Potential acquirers, reverse-merger partners, or asset buyers interested in monetizing remaining intellectual property and reducing transaction friction.
Commercial partners responsible for sales of previously licensed products that generate small royalty receipts for Alaunos.
Alaunos is a U.S.-based company with operations and corporate decision-making centered in the United States...
Alaunos has shifted its strategy from active oncology clinical development to a narrower, lower-cost model centered on...
The obesity program is now the main scientific asset and the best chance to create a differentiated pipeline with a non-hormonal oral mechanism.
Reducing trial and close-out costs is necessary to conserve cash and avoid spending on programs that are no longer strategic.
Asset sales, licensing, or a transaction could provide liquidity and preserve shareholder value if standalone funding is insufficient.
The company expects cash to fund operations only into early 2026, so external capital is required to continue as a going concern.
Alaunos faces acute going-concern and financing risk because it has no product revenue, limited royalty income, and a...
The company has no product revenue, minimal royalty income, and expects cash to fund operations only into the first quarter of 2026.
If the company cannot complete a merger, asset sale, licensing deal, or financing, it may need to curtail operations or dissolve.
Stockholders' equity fell below Nasdaq Capital Market requirements, creating delisting risk and potential financing constraints.
The new lead program is early-stage and may not demonstrate safety, efficacy, or differentiation versus existing obesity therapies.
SEC and FDA delays can impair registration effectiveness, compliance, and transaction execution.
PRLD · Pharmaceutical Preparations
OSTX · Pharmaceutical Preparations
OS Therapies Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapy and targeted cancer candidates.
ALMS · Pharmaceutical Preparations
AGEN · Biological Products, (No Diagnostic Substances)
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
ACRV · Pharmaceutical Preparations
: 11/08/2026